Paper304590
Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.
Mathé G and 2 others. Recent Results Cancer Res, 1977. Cited by 17 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time. Papers, record 304590. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/304590
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Effectiveness of murine leukemia chemotherapy according to the immune state: reconsideration of correlations between chemotherapy, tumour cell killing, and survival time.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cyclophosphamide | Major topic |
| Immunity | Major topic |
| Leukemia L1210 | Major topic |
| Animals | |
| Antilymphocyte Serum | |
| Cell Survival | |
| Immunosuppression Therapy | |
| Mice | |
| Mice, Inbred Strains | |
| T-Lymphocytes |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 8,422,664 | Effect of cisplatin upon expression of in vivo immune tumor resistance. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8422664 | PubMed |
| 8,168,116 | Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy. | Cancer Immunol Immunother | 1994 | https://conductscience.org/library/papers/8168116 | PubMed |
| 6,984,357 | Interference of anti-tumor and immunosuppressive effects of cyclophosphamide in tumor-bearing rats. Analysis of factors determining resistance or susceptibility to a subsequent tumor challenge. | Cancer Immunol Immunother | 1982 | https://conductscience.org/library/papers/6984357 | PubMed |
| 6,553,510 | Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. | Cancer Immunol Immunother | 1983 | https://conductscience.org/library/papers/6553510 | PubMed |
| 3,933,817 | Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor. | Cancer Immunol Immunother | 1985 | https://conductscience.org/library/papers/3933817 | PubMed |
| 3,677,124 | Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/3677124 | PubMed |
| 3,584,212 | Cytocidal and toxic effect of various cytostatic drugs on three ascites tumors of the mouse. | J Cancer Res Clin Oncol | 1987 | https://conductscience.org/library/papers/3584212 | PubMed |
| 3,490,305 | Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/3490305 | PubMed |
| 2,949,833 | In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets. | Cancer Immunol Immunother | 1987 | https://conductscience.org/library/papers/2949833 | PubMed |
| 2,657,252 | Cyclophosphamide and melphalan as immunopotentiating agents in cancer therapy. | Med Oncol Tumor Pharmacother | 1989 | https://conductscience.org/library/papers/2657252 | PubMed |
| 2,337,902 | Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2337902 | PubMed |
| 2,289,208 | Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2289208 | PubMed |
| 1,901,031 | Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. | Cancer Immunol Immunother | 1991 | https://conductscience.org/library/papers/1901031 | PubMed |
| 750,105 | Chemotherapy, a double agent in respect of immune functions. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/750105 | PubMed |
| 535,129 | The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally? | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/535129 | PubMed |
| 161,207 | Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/161207 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/304590
GET https://conductscience.org/api/papers/v1/304590/authors